| |
|
|
|
|
|
|
|||
|
Blood, 1 May 2005, Vol. 105, No. 9, pp. 3394-3395.
Cutaneous lymphomas: it's location, location, locationNATIONAL CANCER INSTITUTE
In this issue, Hoefnagel and colleagues identify anatomic site as a major predictor of the gene expression profile for primary cutaneous large B-cell lymphomas, which segregate into GCB and ABC categories with attendant good and poor prognoses.
Clinicians have recognized that localized primary cutaneous large B-cell lymphomas (PCLBCLs) can be treated conservatively, with local radiation therapy and excellent outcome in most patients.3 However, when Vermeer et al4 proposed that large B-cell lymphomas of the lower leg were distinct, their observations were greeted with considerable skepticism. Why should lymphomas presenting on the lower leg differ from those on the trunk or scalp? That fundamental question is unanswered; however, the current study lends further support to these distinctions. Using gene expression profiling they show that PCLBCLs of the leg and primary cutaneous follicle center cell lymphomas (PCFCCLs) correspond to activated B-cell (ABC) and germinal center B-cell (GCB) types, respectively. These data correlate with other morphologic and immunophenotypic features. PCLBCLs of the leg are composed of cohesive, round cells with little stromal or cellular reaction; they express Bcl-2 (B-cell lymphoma-2) and multiple myeloma oncogene-1/interferon regulatory factor 4 (Mum1/IRF4) proteins; and have a high proliferative rate. Conversely, PCFCCLs are cytologically heterogeneous, often with numerous admixed T cells, a prominent stromal component, and negative staining for Bcl-2 and Mum1/IRF4. Should anatomic site take precedence over other features? Grange et al5 found that Bcl-2 expression and round cell morphology were more important than site alone, suggesting that the "leg-type" of DLBCL may occur in other locations and that defining the disease entity is the preeminent predictor. These concepts have been incorporated in the World Health Organization-European Organization of Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas, which delineates a PCLBCL, leg type, to encompass this tumor on the lower leg and other sites.6
Interestingly, Hoefnagel and colleagues found discordance between Bcl-2 expression by gene array and protein expression within the tumor cells. While they offer a number of explanations, it may be that the Bcl-2 signal in PCFCCLs is derived from background reactive cells rather than tumor cells. Although they attempted to use a restricted set of 7450 B-cell signature genes to focus on the expression profile of the tumor cells, the importance of the background cellular milieu still fell out as a significant discriminator. Genes associated with the "reactive antitumor immune response" were substantially up-regulated in PCFCCLs. This observation reflects the characteristic stromal response seen in these neoplasms and is further indication of the importance of the cellular environment in tumor biology. Notably, Rosenwald et al7 also identified the lymph node signature, associated with the cellular matrix, macrophages, and natural killer cells, as a positive outcome predictor for mainly nodal DLBCLs. More recently, survival in follicular lymphomas also was shown to correlate with tumor-infiltrating immune cells.8 Future studies must focus not only on the intrinsic biology of the tumor cells but also on the host response and tumor environment to further our understanding of lymphoma pathogenesis and progression.
References
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||